JW Therapeutics
- Total Funding$90 M
OverviewSuggest Edit
JW Therapeutics is a biotech company focusing on clinical cell therapy technology. The Company is aimed to develop, transform and promote breakthrough cell-based immunotherapies to fight against cancer.
| Type | Private | |
| Founded | 2016 | |
| HQ | CN | Map |
| Website | jwtherapeutics.com |
Recent NewsAll News
- JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
- JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
- JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting
- JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China
Latest Updates
| Employees (est.) (Aug 2022) | 96 | |
| Cybersecurity rating | A | More |
Key People/Management at JW Therapeutics
Harry Lam
Chief Technology Officer and Senior Advisor
Xin Fu
Senior Vice President and Chief Finance Officer
Shaun Paul Cordoba
Senior Vice President and Chief Scientific Officer
Alex Wu
Senior Vice President and Chief Commercial Officer
James Li
Co-founder, Chairman and Chief Executive Officer
Raymond J. Hage
Senior Vice President, Corporate Development
JW Therapeutics Office Locations
JW Therapeutics has an office in Suzhou Shi
Suzhou Shi, CN
Sang Tian Jie, Wuzhong Qu
JW Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2016 |
JW Therapeutics total Funding | $90 m |
JW Therapeutics latest funding size | $90 m |
Time since last funding | 4 years ago |
JW Therapeutics investors | Temasek Holdings, WuXi AppTec, Juno Therapeutics, YuanMing Capital, Oriza Seed Capital, Sequoia Capital China, AVICT Global Holdings, Yipu Capital |
JW Therapeutics's latest funding round in March 2018 was reported to be $90 m. In total, JW Therapeutics has raised $90 m
JW Therapeutics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Syracuse Biopharma | July 26, 2020 |
JW Therapeutics Cybersecurity Score
JW Therapeutics Online and Social Media Presence
JW Therapeutics's Trends
JW Therapeutics News and Updates
July 04, 2022
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with...
June 05, 2022
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene...
May 09, 2022
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting
SHANGHAI, May 8, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that it will present the latest clinical study data for Carteyva® via...
April 03, 2022
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China
SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products...
February 27, 2022
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted...
January 10, 2022
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building
SHANGHAI, Jan. 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, recently announced the appointments of Dr. Shaun Paul Cordoba as Chief Scientific...
JW Therapeutics Frequently Asked Questions
When was JW Therapeutics founded?
JW Therapeutics was founded in 2016.
Who are JW Therapeutics key executives?
JW Therapeutics's key executives are Harry Lam, Xin Fu and Shaun Paul Cordoba.
How many employees does JW Therapeutics have?
JW Therapeutics has 96 employees.
Who are JW Therapeutics competitors?
Competitors of JW Therapeutics include Neovii, Eutilex and Foghorn Therapeutics.
Where are JW Therapeutics offices?
JW Therapeutics has an office in Suzhou Shi.
How many offices does JW Therapeutics have?
JW Therapeutics has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies